Investment Rating - The report indicates a positive investment outlook for the AI healthcare industry, highlighting significant growth potential and increasing investment activity in the sector [3][10][46]. Core Insights - The AI healthcare sector is entering a new phase characterized by multi-modal integration and practical applications, driven by advancements in large models and generative AI [3][7]. - Clinical decision support and drug development are leading the commercialization efforts, while health management remains an area with untapped potential [3][14]. - The report emphasizes the importance of third-party vendors in reducing model hallucination rates and enhancing the reliability of AI applications in healthcare [3][18][21]. Summary by Sections AI Healthcare Trends - The industry is experiencing heightened investment interest and technological advancements, with major players accelerating their presence in the AI healthcare space [9][10][13]. - The integration of AI into clinical workflows is becoming standard, with AI-assisted diagnosis systems deployed in 89% of tertiary hospitals [8][14]. AI Healthcare Application Penetration - AI applications are diversifying across clinical diagnosis, drug development, health management, and AI for science (AI4S), with varying levels of maturity and market potential [30][31]. - The report identifies key areas of application, including intelligent clinical decision support, drug discovery, and personalized health management [36][39]. Key Companies in AI Clinical Diagnosis - Companies like Tempus AI and 嘉和美康 are leading in AI-assisted clinical diagnosis, focusing on electronic medical records and data-driven healthcare solutions [47][51]. - The report highlights the importance of data barriers and scenario positioning in determining the value of AI diagnostic tools [3][46]. Key Companies in AI Health Management - Companies such as 阿里健康 and 京东健康 are leveraging AI to enhance online healthcare services, with a focus on chronic disease management and personalized health plans [39][44]. - The report notes that the integration of insurance and healthcare services is crucial for the growth of AI health management solutions [39][44]. Key Companies in AI Drug Development - The report discusses the role of AI in accelerating drug development processes, with companies like Recursion and 晶泰控股 focusing on preclinical research and drug discovery [38][44]. - AI is expected to significantly reduce the time and cost associated with traditional drug development methods [38][44]. AI4S and Broader Applications - AI4S is identified as a growing field with applications in various scientific domains, including life sciences and materials science, although it faces longer conversion cycles [42][44]. - The report emphasizes the need for innovative approaches to data generation and modeling in AI4S applications [42][44].

Market Performance - As of July 11, the DRG/DIP concept increased by 2.41%, ranking 9th among concept sectors, with 22 stocks rising, including Jiahe Meikang, Weining Health, and Shanda Diwei, which rose by 5.89%, 5.58%, and 4.94% respectively [1] - The top-performing concept sectors today include Rare Earth Permanent Magnet at 5.64% and MLOps at 3.05%, while sectors like Housing Inspection and PCB saw declines of -1.47% and -1.17% respectively [2] Capital Flow - The DRG/DIP concept sector experienced a net inflow of 141 million yuan, with 11 stocks receiving net inflows, and 6 stocks seeing inflows exceeding 10 million yuan. Weining Health led with a net inflow of 190 million yuan, followed by Di'an Diagnosis, Shanda Diwei, and Donghua Software with net inflows of 25.57 million yuan, 20.81 million yuan, and 15.27 million yuan respectively [2] - In terms of capital inflow ratios, Weining Health, Shanda Diwei, and Di'an Diagnosis had the highest net inflow rates at 14.80%, 9.93%, and 7.13% respectively [3] Stock Performance - The top stocks in the DRG/DIP concept based on today's performance include: - Weining Health: 5.58% increase, 6.57% turnover rate, 189.87 million yuan net inflow, 14.80% net inflow ratio - Di'an Diagnosis: 2.23% increase, 4.75% turnover rate, 25.57 million yuan net inflow, 7.13% net inflow ratio - Shanda Diwei: 4.94% increase, 4.32% turnover rate, 20.81 million yuan net inflow, 9.93% net inflow ratio [3][4]

Core Viewpoint - The announcement details a change in shareholder equity for Jiahe Meikang (Beijing) Technology Co., Ltd., specifically regarding the shareholding of Guoshou Chengda (Shanghai) Health Industry Equity Investment Center (Limited Partnership), which has reduced its stake to 10.00% following a series of share transactions and stock incentive plans [1][2][3]. Summary by Sections 1. Basic Information of the Shareholder - Guoshou Chengda is a limited partnership with a registered capital of 12.01 billion yuan, primarily engaged in equity investment and asset management [1]. - The partnership was established on November 11, 2016, and is managed by Guoshou Chengda (Shanghai) Health Medical Equity Investment Management Co., Ltd. [1]. 2. Details of the Equity Change - Guoshou Chengda executed a share reduction plan, resulting in a total reduction of 3,053,509 shares, bringing its holdings down to 13,758,560 shares, which is 10.00% of the total share capital [2][3]. - The total share capital of the company has changed from 137,877,502 shares to 137,585,598 shares due to the issuance of restricted stocks and stock options [2][3]. 3. Shareholding Situation Before and After the Change - Before the equity change, Guoshou Chengda held 19,569,619 shares, representing 14.1935% of the total share capital [3]. - After the equity change, Guoshou Chengda's holdings decreased to 13,758,560 shares, which is 10.00% of the total share capital [3]. 4. Future Matters - The equity change aligns with previously disclosed plans and commitments by the shareholder [2]. - The company will continue to comply with relevant disclosure regulations and ensure timely updates to investors regarding any further changes [2].

Core Viewpoint - The report outlines a significant reduction in shareholding by Guoshou Chengda (Shanghai) Health Industry Equity Investment Center (Limited Partnership) in Jiahe Meikang (Beijing) Technology Co., Ltd., decreasing its stake to 10% due to financial needs and dilution from stock incentives [1][5]. Group 1: Shareholding Changes - The information disclosure obligor reduced its shareholding from 19,569,619 shares (14.19%) to 13,758,560 shares (10.00%) following a series of transactions [7][8]. - The reduction in shareholding was influenced by the company's issuance of restricted stock and stock options, leading to a dilution of the obligor's stake [5][9]. - The total share capital of Jiahe Meikang was adjusted from 137,877,502 shares to 137,585,598 shares as a result of these changes [8][10]. Group 2: Future Plans - The information disclosure obligor plans to reduce its holdings by up to 4,127,566 shares (3.00% of total shares) within the next 12 months through centralized bidding and block trading [5][6]. - As of the report date, the obligor's reduction plan remains incomplete, and future changes in shareholding are uncertain [5][11]. Group 3: Legal Compliance - The report confirms that the information disclosure obligor has complied with relevant laws and regulations, ensuring the accuracy and completeness of the disclosed information [2][12]. - The obligor has not engaged in any other transactions involving the company's shares in the six months prior to the report [10][13].

证券代码:688246 证券简称:嘉和美康 公告编号：2025-049 嘉和美康（北京）科技股份有限公司 关于修订公司章程的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 嘉和美康（北京）科技股份有限公司（以下简称"公司"）于 2025 年 7 月 份有限公司 2025 年第三次临时股东会增加临时提案的函》，根据公司实际经营 情况和发展需要，公司新设联席总经理岗位，相应修订公司章程，本事项尚需提 交 2025 年第三次临时股东会审议。具体情况如下： 一、修订《公司章程》的原因 根据公司实际经营情况和发展需要，公司新设联席总经理岗位，相应修订公 司章程。 二、《公司章程》修订情况 修订前 修订后 第十二条 本章程所称高级管理人员是 第十二条 本章程所称高级管理人员 指公司的总经理、副总经理、财务负责 是指公司的总经理、联席总经理、副 人、董事会秘书和本章程规定的其他人 总经理、财务负责人、董事会秘书和 员。 本章程规定的其他人员。 第一百一十一条 董事会行使下列职 第一百一十一条 董事会行使下列职 权： 权： …… … ...

嘉和美康（北京）科技股份有限公司 简式权益变动报告书 上市公司名称：嘉和美康（北京）科技股份有限公司 股票上市地点：上海证券交易所 股票简称：嘉和美康 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购办法》"）、《公开发行证券的公司信 息披露内容与格式准则第 15 号——权益变动报告书》（以下简称"准则 15 号"） 及相关的法律、法规编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《证券法》《收购办法》、准则 15 号的规定，本报告书已全面披露 了信息披露义务人在嘉和美康（北京）科技股份有限公司中拥有权益的股份变动 情况。 四、截至本报告书签署之日，除本报告书披露的持股信息外，信息披露义务 人没有通过任何其他方式增加或减少其在嘉和美康（北京）科技股份有限公司中 拥有权益的股份。 五、本次权益变动是根据本报告书所载明的资料进行的。信息披露义务人没 有委托或者授权其他任何人提供未在本报告书中列载的信息和对本报告书做出 任 ...

证券代码：688648 证券简称：嘉和美康 公告编号：2025-047 嘉和美康（北京）科技股份有限公司 关于股东权益变动触及 5%整数倍的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次权益变动为国寿成达（上海）健康产业股权投资中心（有限合伙）（以下 简称"国寿成达"）履行此前披露的减持股份计划，及因嘉和美康（北京）科技股 份有限公司（以下简称"公司"）向激励对象授予限制性股票、期权行权导致公司 总股本增加，持股比例被动稀释，以及因公司注销回购股份导致公司总股本减少， 持股比例被动增加，不触及要约收购。 本次权益变动后，国寿成达合计持有公司股份 13,758,560 股，占公司目前总 股本的 10.00%，持股比例触及 5%的整数倍。 本次权益变动不会导致公司控股股东、实际控制人发生变化，不会对公司治 理结构及未来持续经营产生重大影响。 公司于近日收到股东国寿成达出具的《简式权益变动报告书》，现将有关权益 变动情况公告如下： 一、本次权益变动基本情况 （一）信息披露义务人的基本情况 | 企 ...

嘉和美康（北京）科技股份有限公司 章 程 2025 年 7 月 | 第一章 | 总则 1 | | --- | --- | | 第二章 | 经营宗旨和范围 2 | | 第三章 | 股份 2 | | 第一节 | 股份发行 2 | | 第二节 | 股份增减和回购 4 | | 第三节 | 股份转让 5 | | 第四章 | 股东和股东会 6 | | 第一节 | 股东 6 | | 第二节 | 控股股东和实际控制人 8 | | 第三节 | 股东会的一般规定 9 | | 第四节 | 股东会的召集 12 | | 第五节 | 股东会的提案与通知 14 | | 第六节 | 股东会的召开 15 | | 第七节 | 股东会的表决和决议 18 | | 第五章 | 董事和董事会 22 | | 第一节 | 董事的一般规定 22 | | 第二节 | 董事会 25 | | 第三节 | 独立董事 29 | | 第四节 | 董事会专门委员会 32 | | 第六章 | 高级管理人员 33 | | 第七章 | 财务会计制度、利润分配和审计 35 | | 第一节 | 财务会计制度 35 | | 第二节 | 内部审计 39 | | 第三节 | 会计师事务所 ...

证券代码:688246 证券简称:嘉和美康 公告编号：2025-049 嘉和美康（北京）科技股份有限公司 关于修订公司章程的公告 二、《公司章程》修订情况 | 会秘书及其他高级管理人员，并决定其 | 席总经理、董事会秘书及其他高级管 | | --- | --- | | 报酬事项和奖惩事项；根据总经理的提 | 理人员，并决定其报酬事项和奖惩事 | | 名，决定聘任或者解聘公司副总经理、 | 项；根据总经理的提名，决定聘任或 | | 财务负责人等高级管理人员，并决定其 | 者解聘公司副总经理、财务负责人等 | | 报酬事项和奖惩事项； | 高级管理人员，并决定其报酬事项和 | | | 奖惩事项； | | …… | | | | …… | | （十四）听取公司总经理的工作汇报并 | | | 检查总经理、联席总经理的工作； | （十四）听取公司总经理、联席总经 | | | 理的工作汇报并检查总经理、联席总 | | | 经理的工作； | | 第一百一十四条 公司发生的交易（提 | 第一百一十四条 公司发生的交易 | | 供担保除外）达到下列标准之一的，应 | （提供担保除外）达到下列标准之一 | | 当提交董事会审议批准 ...

| 目 | 录 | | | --- | --- | --- | | 2025 年第三次临时股东会会议须知 2 | | | | 2025 年第三次临时股东会会议议程 4 | | | | 2025 年第三次临时股东会会议议案 6 | | | | 议案一：关于修订公司章程的议案 | | 6 | | 议案二：关于公司董事会换届选举第五届董事会非独立董事的议案 | | 7 | | 议案三：关于公司董事会换届选举第五届董事会独立董事的议案 | | 8 | 1 嘉和美康（北京）科技股份有限公司 证券代码：688246 证券简称：嘉和美康 嘉和美康（北京）科技股份有限公司 2025 年第三次临时股东会会议资料 2025 年 7 月 15 日 2025 年第三次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证大 会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东会规则》以及《公司章程》《股东会议事规则》等相关规定，特制定 嘉和美康（北京）科技股份有限公司（以下简称"公司"）2025 年第三次临时 股东会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者 ...